4.5 Article

MicroRNA-622 is a novel mediator of tumorigenicity in melanoma by targeting Kirsten rat sarcoma

Journal

PIGMENT CELL & MELANOMA RESEARCH
Volume 31, Issue 5, Pages 614-629

Publisher

WILEY
DOI: 10.1111/pcmr.12698

Keywords

KRAS; melanoma; microRNA

Funding

  1. Deutsche Forschungsgemeinschaft [FOR2172, BO1573]
  2. Bayerisches Staatsministerium fur Wissenschaft, Forschung und Kunst
  3. Staedtler Stiftung
  4. Deutsche Krebshilfe
  5. Interdisciplinary Center for Clinical Research (IZKF) Erlangen [J55, D24]

Ask authors/readers for more resources

The network of molecular players is similar when comparing neural crest-derived, actively migrating melanoblasts to melanoma cells. However, melanoblasts are sensitive to differentiation-initiating signals at their target site (epidermis), while melanoma cells maintain migratory and undifferentiated features. We aimed at identifying downregulated genes in melanoma that are particularly upregulated in melanoblasts. Loss of such genes could contribute to stabilization of a dedifferentiated, malignant phenotype in melanoma. We determined that microRNA-622 (miR-622) expression was strongly downregulated in melanoma cells and tissues compared to melanocytes and melanoblast-related cells. miR-622 expression correlated with survival of patients with melanoma. miR-622 re-expression inhibited clonogenicity, proliferation, and migration in melanoma. Inhibition of miR-622 in melanocytes induced enhanced migration. Kirsten rat sarcoma (KRAS) was identified as a major functional target of miR-622 in melanoma. We conclude that miR-622 is a novel tumor suppressor in melanoma and identify the miR-622-KRAS axis as potential therapeutic target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available